Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10235 IDEX CORPORATION Registrant's telephone number: (847) 498-7070 Securities registered pursuant to Section 12(b) of ...

IDEX Corporation (NYSE:IEX) Q2 2020 Earnings Conference Call July 24, 2020 10:30 AM ET Company Participants Mike Yates - Vice President and Chief Accounting Officer Andy Silvernail - Chairman and Chief Executive Officer Bill Grogan - Senior Vice President and Chief Financial Officer Conference Call Participants Mike Halloran - Baird Deane Dray - RBC Capital Markets Matt Summerville - D.A. Davidson Allison Poliniak - Wells Fargo Nathan Jones - Stifel Scott Graham - Rosenblatt Securities Operator Greetings, a ...

Second Quarter 2020 Earnings July 24, 2020 Fluid & Metering Health & Science Fire & Safety / Diversified Trusted Solutions, Improving Lives™ Agenda IDEX Business Overview • Q2 Overview • COVID-19 • End Market Update Financials • Q2 Performance • Operating Profit • Liquidity Q3 Summary Q&A IDEX Proprietary & Confidential 2 Replay Information • International: 201.612.7415 • Dial toll–free: 877.660.6853 • Conference ID: #13694805 • Log on to: www.idexcorp.com IDEX Proprietary & Confidential 3 Cautionary Statem ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10235 IDEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 36-3555336 (State or other jurisdicti ...

IDEX Corporation (NYSE:IEX) Q1 2020 Earnings Conference Call April 24, 2020 10:30 AM ET Company Participants Mike Yates - Vice President and Chief Accounting Officer Andrew Silvernail - Chairman and Chief Executive Officer William Grogan - Senior Vice President and Chief Financial Officer Conference Call Participants Deane Dray - RBC Capital Markets Michael Halloran - Robert W. Baird & Co., Inc. Scott Graham - Rosenblatt Securities Inc. Nathan Jones - Stifel Nicolaus and Company, Incorporated Allison Polini ...

For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10235 IDEX CORPORATION (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation ...

First Quarter 2020 Earnings April 24, 2020 Fluid & Metering Health & Science Fire & Safety / Diversified Trusted Solutions, Improving Lives™ Agenda IDEX Performance Drivers COVID 19 Financials • Q1 Performance • Liquidity • Break Even Analysis Q2 Summary Q&A IDEX Proprietary & Confidential 2 Replay Information • International: 201.612.7415 • Dial toll–free: 877.660.6853 • Conference ID: #13694804 • Log on to: www.idexcorp.com IDEX Proprietary & Confidential 3 Cautionary Statement Cautionary Statement Under ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10235 IDEX CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-3555336 (State or other jurisdiction of incorporation or or ...

Financial Data and Key Metrics Changes - In Q4 2019, orders were $617 million, up 1% overall but flat organically, with a slowdown in industrial markets impacting performance [19] - Q4 sales were $606 million, down 1% overall and down 2% organically, with full year sales of $2.5 billion flat overall and up 1% organically [20][21] - Q4 gross margins contracted 60 basis points to 44%, while full year gross margins expanded 10 basis points [22] - Adjusted net income for Q4 was $102 million, resulting in an adjusted EPS of $1.33, up 2% year-over-year, with full year adjusted EPS at $5.80, up 7% [25] Business Line Data and Key Metrics Changes - Fluid & Metering segment saw Q4 orders down 5% overall and down 4% organically, with full year orders flat overall but up 2% organically [26] - Health & Science segment had Q4 orders up 6% overall and 3% organically, with full year orders flat overall and down 1% organically [31] - Diversified segment reported Q4 orders up 1% overall and 2% organically, with full year orders down 2% overall and flat organically [36] Market Data and Key Metrics Changes - The industrial market showed significant softness, with U.S. industrial production posting the lowest results in a decade [28] - The agricultural market remains pressured due to tariff impacts and low commodity prices, with cautious optimism from the Phase 1 trade deal [28] - The semiconductor and automotive markets experienced declines, contributing to overall market challenges [31] Company Strategy and Development Direction - The company is focused on long-term profitable growth through strategic pricing and productivity initiatives, with a restructuring plan expected to yield $15 million in savings for 2020 [12][13] - The acquisition of Flow Management Devices is seen as a strategic move to enhance growth in the oil and gas sector, with expected margin expansion [15] - The company plans to continue investing in organic growth opportunities while maintaining a disciplined approach to capital deployment [17][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a weakened global economy and anticipated continued challenges in the first half of 2020, with expectations for organic revenue to be flat to down 2% [12][40] - The company is confident in its ability to control costs and execute its strategy despite market headwinds [14][39] - Management indicated that while there are challenges, the diversified portfolio and strong balance sheet position the company well for future opportunities [14] Other Important Information - The effective tax rate for Q4 was 20.6%, lower than the previous year due to one-time tax benefits [24] - Free cash flow for the year reached a record $477 million, up 13% from the previous year [25] Q&A Session Summary Question: Can you discuss the decline in orders and the market environment? - Management noted that while industrial markets are not worsening, the overall order rate was affected by a strong performance in previous quarters and general industrial softness [49][50] Question: What is embedded in the guidance for 2020? - The guidance reflects a modest improvement in the second half of the year, with no aggressive recovery assumed [53] Question: Can you elaborate on the targeted growth initiatives? - Management explained that three successful initiatives from previous years are not repeating, leading to a $30 million headwind for 2020 [61][62] Question: What are the expectations for life sciences and industrial growth in 2020? - Life sciences are expected to grow at 5% to 6%, while industrial segments are anticipated to contract by about 3% [94][96] Question: How is the company addressing potential further market deterioration? - Management has already implemented cost reductions and has plans for additional variable cost cuts if necessary [88][108]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 1-10235 IDEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 36-3555336 (State or other jurisdiction of incorporation or organi ...